You are here

FDA Approves Generic Synthroid Tablets

PITTSBURGH, June 24 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE:MYL) today announced that the U.S. Food and Drug Administration (FDA) has granted final approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Levothyroxine Sodium Tablets in 0.025 mg, 0.050 mg, 0.075 mg, 0.088 mg, 0.1 mg, 0.112 mg, 0.125 mg, 0.15 mg, 0.175 mg, 0.2 mg and 0.3 mg strengths.

Levothyroxine Sodium Tablets are the generic version of Abbott Laboratories' Synthroid(R) Tablets.

"We are very pleased with this product approval," stated Robert J. Coury, Mylan's Vice Chairman and CEO. "This approval represents a very important addition to our product portfolio and finally brings closure to some of the tactics used by others to delay legitimate generic approvals."

The product will be shipped immediately.

Source: Mylan Laboratories, Inc.

Recent Headlines

Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission
Researchers Extend Previous Data, Find Association is Reversed
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
New Test Could Prevent Short- and Long-term Complications